|By PR Newswire||
|April 11, 2014 01:00 PM EDT||
DUBLIN, Ireland, April 11, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/53hl65/global) has announced the addition of the "Global Epinephrine Auto-Injector Market Report" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The analysts forecast the Global Epinephrine Auto-injector market to grow at a CAGR of 13.34 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of allergies. The Global Epinephrine Auto-injector market has also been witnessing the development of chlorofluorocarbon-free epinephrine auto-injector inhalers. However, the adverse side-effects of epinephrine drugs could pose a challenge to the growth of this market.
The report, the Global Epinephrine Auto-injector Market Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas and the EMEA and APAC regions; it also covers the Global Epinephrine Auto-injector market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The inhalers used for the treatment of asthma patients in the past combined a mixture of epinephrine powder and CFC as an aerosol. However, the government in the US imposed a ban on the use of CFC as a propellant in inhalers. Primatene Mist, the only FDA-approved over-the-counter epinephrine inhaler containing CFC, was pulled by the FDA on December 31, 2011. Primatene Mist was the only FDA-approved epinephrine inhaler available in the market for the temporary relief of occasional symptoms of mild asthma. Hence, vendors are increasing their investment in R&D to develop a CFC-free epinephrine inhaler using hydrofluoroalkane as a propellant.
According to the report, though epinephrine is produced in the body, chemically synthesized epinephrine drugs are used in the treatment of anaphylactic shock that occurs in people who are suffering from allergy, cardiac arrest, and asthma. The increase in the number of people who are allergic to food, food additives, dust, and insect venom has led to an increase in the use of epinephrine drugs. This is one of the major factors that drive the growth of the Global Epinephrine Auto-injector market.
Further, the report states that one of the main challenges in the market is that epinephrine drugs can cause adverse side effects such as vomiting, cardiac arrhythmia, hyperuricemia, lactic acidosis, pulmonary edema, and cerebral hemorrhage. Hence, physicians prefer to prescribe immunotherapy and other alternative pharmacotherapy drugs for the treatment of allergies.
Key Topics Covered:
1. Executive Summary
2. List of Abbreviations
4. Market Research Methodology
5. Scope of the Report
6. Market Landscape
7. Geographical Segmentation
8. Key Leading Countries
9. Rate of Incidence and Prevalence
10. Vendor Landscape
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Key Vendor Analysis
- Adamis Pharmaceuticals Corp.
- ALK Abello
- Amedra Pharmaceuticals
- Antares Pharma
- Lincoln Medical
- Teva Pharmaceuticals Industries
For more information visit http://www.researchandmarkets.com/research/53hl65/global
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
Aug. 28, 2016 08:30 PM EDT Reads: 1,797
Deploying applications in hybrid cloud environments is hard work. Your team spends most of the time maintaining your infrastructure, configuring dev/test and production environments, and deploying applications across environments – which can be both time consuming and error prone. But what if you could automate provisioning and deployment to deliver error free environments faster? What could you do with your free time?
Aug. 28, 2016 08:15 PM EDT Reads: 1,924
Aug. 28, 2016 07:30 PM EDT Reads: 667
Aug. 28, 2016 06:30 PM EDT Reads: 1,598
Aug. 28, 2016 06:00 PM EDT Reads: 1,912
Aug. 28, 2016 05:30 PM EDT Reads: 720
Aug. 28, 2016 03:15 PM EDT Reads: 3,482
Aug. 28, 2016 03:00 PM EDT Reads: 737
Aug. 28, 2016 01:45 PM EDT Reads: 3,651
Aug. 28, 2016 01:00 PM EDT Reads: 2,416
Aug. 28, 2016 12:15 PM EDT Reads: 843
Aug. 28, 2016 11:45 AM EDT Reads: 679
Aug. 28, 2016 11:30 AM EDT Reads: 1,952
Aug. 28, 2016 11:00 AM EDT Reads: 696
Aug. 28, 2016 11:00 AM EDT Reads: 3,122